AU2001280804A1 - Aldosterone blocker therapy to prevent or treat inflammation-related disorders - Google Patents
Aldosterone blocker therapy to prevent or treat inflammation-related disordersInfo
- Publication number
- AU2001280804A1 AU2001280804A1 AU2001280804A AU8080401A AU2001280804A1 AU 2001280804 A1 AU2001280804 A1 AU 2001280804A1 AU 2001280804 A AU2001280804 A AU 2001280804A AU 8080401 A AU8080401 A AU 8080401A AU 2001280804 A1 AU2001280804 A1 AU 2001280804A1
- Authority
- AU
- Australia
- Prior art keywords
- prevent
- related disorders
- treat inflammation
- blocker therapy
- aldosterone blocker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22135800P | 2000-07-27 | 2000-07-27 | |
| US60/221,358 | 2000-07-27 | ||
| US26135201P | 2001-01-12 | 2001-01-12 | |
| US60/261,352 | 2001-01-12 | ||
| PCT/US2001/023520 WO2002009683A2 (en) | 2000-07-27 | 2001-07-26 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001280804A1 true AU2001280804A1 (en) | 2002-02-13 |
Family
ID=26915708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001280804A Abandoned AU2001280804A1 (en) | 2000-07-27 | 2001-07-26 | Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030162759A1 (en) |
| EP (1) | EP1368009A2 (en) |
| JP (1) | JP2004518611A (en) |
| AU (1) | AU2001280804A1 (en) |
| CA (1) | CA2416152A1 (en) |
| WO (1) | WO2002009683A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006508174A (en) * | 2002-01-25 | 2006-03-09 | ファルマシア・コーポレーション | Aldosterone blocker therapy to prevent or treat inflammation-related diseases |
| WO2003080069A1 (en) * | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent |
| BR0313693A (en) * | 2002-08-23 | 2007-08-14 | Pharmacia Corp | modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker (s) |
| US7786101B2 (en) | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
| EP1558265B1 (en) * | 2002-11-05 | 2010-01-06 | Bayer Schering Pharma Aktiengesellschaft | Use of drospirenone for the treatment of hypertension |
| WO2004041288A1 (en) * | 2002-11-05 | 2004-05-21 | Schering Aktiengesellschaft | Hormone replacement therapy with drospirenone |
| US8409815B2 (en) | 2002-11-16 | 2013-04-02 | Siemens Healthcare Diagnostics Products Gmbh | sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases |
| US20050014732A1 (en) * | 2003-03-14 | 2005-01-20 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
| US20070123498A1 (en) * | 2003-10-17 | 2007-05-31 | Shetty Suraj S | Combination of organic compounds |
| WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| CN101505795B (en) * | 2006-07-03 | 2013-02-13 | 查尔斯·戴维·阿代尔 | Compositions for modulating expression of cell adhesion molecules |
| EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
| US20090089628A1 (en) * | 2007-10-01 | 2009-04-02 | Day Mark S | File system error detection and recovery framework |
| AU2009306404B2 (en) | 2008-10-24 | 2015-01-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Biomarkers of Mineralocorticoid Receptor activation |
| US20120058205A1 (en) * | 2009-03-04 | 2012-03-08 | Walter Howard Peschel | Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia |
| DE102011015142A1 (en) * | 2011-03-17 | 2012-09-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Agent for the prophylaxis and treatment of age-associated diseases and disorders and for extending the life |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2652761C2 (en) * | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-methylene-spirolactones, processes for their preparation and pharmaceuticals containing them |
| US5134150A (en) * | 1985-12-12 | 1992-07-28 | Smithkline Beecham Corporation | Inhibition of the 5-lipoxygenase pathway |
| US5348729A (en) * | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| US5550124A (en) * | 1991-12-10 | 1996-08-27 | University Of Southern California | Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease |
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| AU2385795A (en) * | 1994-04-12 | 1995-10-30 | Alza Corporation | Screening methods for integumental inflammation modulating agents |
| AU4777896A (en) * | 1995-02-10 | 1996-08-27 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| JPH0971586A (en) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | New bicyclic condensed imidazole derivative |
| EP1920773B1 (en) * | 1996-11-05 | 2011-01-05 | The Children's Medical Center Corporation | Thalidomide and dexamethasone for the treatment of tumors |
| WO1999058117A1 (en) * | 1998-05-13 | 1999-11-18 | Sanofi-Synthelabo | Use of compounds for reducing apoptosis |
| EP1077702A1 (en) * | 1998-05-22 | 2001-02-28 | The University Of British Columbia | Peripheral benzodiazepine receptor ligands |
| WO2000010552A2 (en) * | 1998-08-24 | 2000-03-02 | Global Vascular Concepts, Inc. | Use of anti-angiogenic agents for inhibiting vessel wall injury |
| UA74141C2 (en) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants) |
| ES2288487T3 (en) * | 1999-11-09 | 2008-01-16 | Pharmacia Corporation | USE OF EPLERENONE FOR TREATMENT OF RESTENOSIS. |
| EP1282410A2 (en) * | 2000-04-12 | 2003-02-12 | Novartis AG | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| AU1604001A (en) * | 2000-06-13 | 2001-12-24 | Pharmacia Corp | Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
-
2001
- 2001-07-26 EP EP01959222A patent/EP1368009A2/en not_active Withdrawn
- 2001-07-26 WO PCT/US2001/023520 patent/WO2002009683A2/en not_active Ceased
- 2001-07-26 AU AU2001280804A patent/AU2001280804A1/en not_active Abandoned
- 2001-07-26 US US09/916,136 patent/US20030162759A1/en not_active Abandoned
- 2001-07-26 JP JP2002515236A patent/JP2004518611A/en not_active Withdrawn
- 2001-07-26 CA CA002416152A patent/CA2416152A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002009683A2 (en) | 2002-02-07 |
| EP1368009A2 (en) | 2003-12-10 |
| JP2004518611A (en) | 2004-06-24 |
| WO2002009683A9 (en) | 2003-06-12 |
| US20030162759A1 (en) | 2003-08-28 |
| CA2416152A1 (en) | 2002-02-07 |
| WO2002009683A3 (en) | 2003-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001280804A1 (en) | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | |
| AU2001257342A1 (en) | Treatment well tiltmeter system | |
| AU3920900A (en) | Compounds and methods to treat cardiac failure and other disorders | |
| AU2002223827A1 (en) | Well treatment | |
| AU2001282717A1 (en) | Cancer treatment by combination therapy | |
| AU2002210463A1 (en) | Transdermal therapeutic system | |
| AU2002210462A1 (en) | Transdermal therapeutic system for treating restless-legs-syndrome | |
| AU2001251011A1 (en) | Treatments for immune-mediated ear disorders | |
| AU7360000A (en) | Methods and compositions for preventing and treating prostate disorders | |
| AU7377200A (en) | Combination therapy including camptothecin | |
| AU2660099A (en) | Readily absorbable phytosterols to treat hypercholesterrolemia | |
| AU2001222215A1 (en) | Lumbago treating girdle | |
| AU2002249779A1 (en) | Method to treat hemophilia | |
| AU2002230888A1 (en) | Methods and compositions to treat conditions associated with neovascularization | |
| AU2002222240A1 (en) | Nerve regeneration | |
| AUPR074500A0 (en) | Treatment of t cell disorders | |
| AU2001227972A1 (en) | Methods to treat alpha-1-antitrypsin deficiency | |
| AU5042000A (en) | Methods of treating proliferative disorders | |
| AU2001229597A1 (en) | Compositions and methods to treat neurodegenerative disorders | |
| AU1449501A (en) | Iontophoretic treatment system | |
| AU2001294183A1 (en) | Waste treatment equipment | |
| PL373391A1 (en) | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | |
| AU2080201A (en) | Treatment of addiction disorders | |
| AU2000231423A1 (en) | Specific therapeutic composition for treating aids | |
| AU2001261324A1 (en) | Psoriasis treatment |